FOLR1

FOLR1

FOLR1 Overview

Molecule Name
Folate receptor alpha
Synonyms
FOLR-1,FBP,FOLR,FRα
Drug Development Progress
Drugs in Clinical Trials27
Approved Drugs3
Highest Development StageApproved
Target Synonym
FRalpha,KB cells FBP,Adult folate-binding protein,Folate receptor 1,Folate receptor alpha,FR-alpha,FOLR1,Ovarian Tumor-Associated Antigen MOv18,Folate Receptor 1 (Adult),Folate Receptor, Adult,FOLR,FBP,Folate Binding Protein,FRα
Background
Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

FOLR1 Product List

Species
  • Human(13)
  • Mouse(6)
  • Cynomolgus / Rhesus macaque(4)
Tag
  • His Tag(11)
  • His Tag & Avi Tag(6)
  • Fc Tag(4)
  • Fc Tag & Avi Tag(2)
Host
  • HEK293(23)
Conjugate
  • Unconjugated(11)
  • Biotin-labeled(8)
  • PE Labeled(2)
  • APC Labeled(1)
  • FITC Labeled(1)
Grade
  • RUO(23)
Low Endotoxin
  • Yes(1)
  • No(22)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
FOLR1
Human FOLR1 Protein, His Tag
Human
HEK293
HPLCSDS-PAGE
SPR

$1310.00

250ug
FOLR1
Human FOLR1 Protein, Fc Tag (Folic Acid Free, MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$310.00

100ug
FOLR1
HOTAvitag
FO1-H82E2
Biotinylated Human FOLR1 Protein, His,Avitag™ (Folic Acid Free, MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRFlow

$495.00

25ug
FOLR1
Human FOLR1 Protein, His Tag, low endotoxin (Folic Acid Free, Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$455.00

100ug
FOLR1
HOTAvitag
FO1-M82E9
Biotinylated Mouse FOLR1 Protein, His,Avitag™ (Folic Acid Free, MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
FOLR1
Cynomolgus / Rhesus macaque FOLR1 Protein, His tag (Folic Acid Complex, MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$465.00

100ug
FOLR1
Cynomolgus / Rhesus macaque FOLR1 Protein, His tag (Folic Acid Free, MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$465.00

100ug
FOLR1
Avitag
FO1-C82E8
Biotinylated Cynomolgus / Rhesus macaque FOLR1 Protein, His,Avitag™ (Folic Acid Free, MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$380.00

25ug
FOLR1
Avitag
FO1-C82E9
Biotinylated Cynomolgus / Rhesus macaque FOLR1 Protein, His,Avitag™ (Folic Acid Complex, MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$368.00

25ug
FOLR1
Human FOLR1 Protein, Fc Tag (Folic Acid Complex, MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$310.00

100ug
You Have Viewed 1-10 Of 23 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

Before a FOLR1-targeted antibody or ADC advances into nonclinical studies, which mammalian-expressed FOLR1 orthologs are available for cross-species binding assessment?

The ACROBiosystems recombinant protein portfolio includes human, mouse, and cynomolgus/rhesus macaque FOLR1, with HEK293-expressed His-tagged and selected biotinylated His-AviTag™ formats. Folic Acid Free and Folic Acid Complex availability and quality-characterization packages vary by construct. HEK293 expression supports mammalian protein folding and glycosylation, but the available data do not demonstrate species-native glycoform equivalence or establish that these reagents alone satisfy IND filing requirements.

For SPR or BLI characterization of FOLR1-targeted antibodies, how should a biotinylated antigen format be selected when capture orientation and target valency may affect the apparent binding kinetics?

ACROBiosystems offers biotinylated FOLR1 proteins in His-AviTag™ and Fc-AviTag™ formats. The His-AviTag™ format uses enzymatic biotinylation at the single lysine within the AviTag™ and provides a non-Fc antigen for streptavidin-based capture. The Fc-AviTag™ format introduces Fc-mediated dimerization and is more appropriate when bivalent target presentation is intentional rather than when monovalent affinity is required. Site-specific biotinylation supports controlled capture but does not, by itself, demonstrate that the ligand-binding pocket is entirely unaffected.

How can FOLR1 proteins be used to evaluate FOLR1-targeting antibodies or CARs?

Recombinant FOLR1 proteins can support antibody-binding studies, while labeled formats can serve as probes for cell-based detection. For example, FO1-H82E2 has documented flow cytometry binding activity with anti-FOLR1 CAR-293 cells. These binding results do not independently establish CAR-T functional activity.

In competitive binding or ligand-blocking studies, pre-bound folic acid may obscure the FOLR1 binding pocket. How do the available FOLR1 protein formats address this potential interference?

ACROBiosystems offers separate Folic Acid Free and Folic Acid Complex FOLR1 proteins. For applications sensitive to ligand occupancy, the Folic Acid Free formats are intended to minimize interference from pre-bound folate and have demonstrated folic acid-binding activity. SDS-PAGE and SEC-MALS characterize protein purity and molecular-weight distribution but do not directly quantify residual ligand occupancy.

What is the difference between folic acid-free and folic acid-complexed FOLR1 proteins?

Folic acid-free FOLR1 is supplied without folic acid complexation, while folic acid-complexed FOLR1 is supplied in a ligand-associated form. This distinction matters when studying folate binding or ligand-dependent interactions. Choose the format according to the intended assay and review the product-specific validation data.
Asset Licensing Opportunity

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
FRα BsAb - 01PCCBispecificHumanized Mouse,NanobodySolid TumorOvarian cancer,Non-small cell lung cancer
Project Name
FRα BsAb - 01
Project Stage
PCC
Molecule Type
Bispecific
Molecule Source
Humanized Mouse,Nanobody
Disease Area
Solid Tumor
Indication
Ovarian cancer,Non-small cell lung cancer

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
FRα BsAb-ADCBispecific antibodyOncology/CancerOvarian cancerPreclinicalGlobal
Project Name
FRα BsAb-ADC
Drug Type
Bispecific antibody
Therapeutic Area
Oncology/Cancer
Indication
Ovarian cancer
Stage
Preclinical
Rights Area
Global
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Ricorfotide vedotinCBP-1008Phase 3 ClinicalCoherent Biopharma Suzhou Co Ltd
Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours
Details
ArfolitixorinISO-901; 6R-MTHFPhase 3 ClinicalIsofol Medical Ab
Colonic Neoplasms; Colorectal Neoplasms; Osteosarcoma; Rectal Neoplasms
Details
Rinatabart SesutecanGEN1184; GEN-1184; PRO-1184Phase 3 ClinicalProfoundBio (Suzhou) Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Neoplasms
Details
Sofetabart MipitecanLY4170156; LY-4170156Phase 3 ClinicalEli Lilly And Company, Loxo Oncology Inc
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
Details
Torvutatug SamrotecanAZD5335; AZD-5335Phase 3 ClinicalAstrazeneca Plc
Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Diseases; Solid tumours
Details
BAT-8006BAT8006; BAT-8006Phase 3 ClinicalBio-Thera Solutions Ltd
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours
Details
Luveltamab tazevibulinSTRO-002Phase 2 ClinicalSutro Biopharma Inc
Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours
Details
EB-NK-FM (FRalpha/MUC16)EB-NK-FMPhase 2 ClinicalBeijing Biotech
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Details
EB-NK-MF (MSLN/FRalpha)EB-NK-MFPhase 2 ClinicalBeijing Biotech
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Glioblastoma; Glioma; Peritoneal Neoplasms
Details
18F-AzaFolAzaFol; 18F-AzaFol; [18F]-AzaFolPhase 2 ClinicalInsel Gruppe AG, University Hospital Bern
Giant Cell Arteritis; Lung Neoplasms; Neoplasms; Ovarian Neoplasms
Details
Farletuzumab ecteribulinMORAb-202Phase 2 ClinicalBristol-Myers Squibb Company, Eisai Co Ltd, Morphotek Inc
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Solid tumours
Details
4S-CAR-FRa4S-CAR-FRaPhase 2 ClinicalShenzhen Geno-Immune Medical Institute
Carcinoma, Transitional Cell; Urinary Bladder Neoplasms
Details
CBP-1019CBP-1019Phase 2 ClinicalCoherent Biopharma Suzhou Co Ltd
Breast Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Thoracic Neoplasms; Urogenital Neoplasms
Details
Noscapine-folate conjugatePhase 1 ClinicalEmory University
Hematologic Neoplasms; Inflammation
Details
MOv-18 IgEMOv-18 IgE; MOv18; MOv-18Phase 1 ClinicalCancer Research UK, King'S College London
Neoplasms; Ovarian Neoplasms
Details
MOv19-BBz CAR-T cells TherapyPhase 1 ClinicalUniversity Of Pennsylvania
Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Details
ITIL-306ITIL-306Phase 1 ClinicalInstil Bio Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Genital Neoplasms, Female; Solid tumours
Details
IMGN-151IMGN-151Phase 1 ClinicalImmunogen Inc
Breast Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms
Details
GenSci-140GenSci140; GenSci-140Phase 1 ClinicalChangchun GeneScience Pharmaceuticals Co Ltd
Ovarian Neoplasms; Solid tumours
Details
IBI-3010IBI-3010; IBI3010Phase 1 Clinical
Neoplasm Metastasis; Solid tumours
Details
SYS-6041SYS6041; SYS-6041Phase 1 ClinicalJushi Biopharmaceutical Co Ltd
Neoplasms; Solid tumours
Details
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy(Fred Hutchinson Cancer Center)Phase 1 ClinicalFred Hutchinson Cancer Research Center
Leukemia, Myeloid, Acute; Osteosarcoma
Details
[177Lu]Lu-EVS459GIZ943; GIZ-943; [177Lu]Lu-EVS459; EVS-459Phase 1 ClinicalNovartis Pharma Ag
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Ovarian Neoplasms
Details
ZW-191ZW-191Phase 1 ClinicalZymeworks Inc
Carcinoma, Non-Small-Cell Lung; Genital Neoplasms, Female; Ovarian Neoplasms; Solid tumours
Details
AMT-151AMT-151Phase 1 ClinicalMultitude Therapeutics Inc
Adenocarcinoma of Lung; Adenocarcinoma, Clear Cell; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
UB-TT170UB-TT-170; UB_TT170; UB_TT-170; UB-TT170Phase 1 ClinicalUmoja BioPharma Inc
Osteosarcoma
Details
CBP-1018CBP-1018Phase 1 ClinicalCoherent Biopharma Suzhou Co Ltd
Carcinoma, Renal Cell; Lung Neoplasms; Prostatic Neoplasms; Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Pafolacianine SodiumPteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038ApprovedOn Target Laboratories IncCytaluxUnited StatesOvarian NeoplasmsOn Target Laboratories Inc2021-11-29
Arthritis, Rheumatoid; Breast Neoplasms; Esophageal Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Inflammatory Bowel Diseases; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Pituitary Neoplasms
Details
Mirvetuximab soravtansineM9346-Asulfo-SPDB-DM4; IMGN-853; M9346A-sSPDB-DM4; TAK-853; HDM2002; HDM-2002ApprovedImmunogen IncElahere, 爱拉赫United StatesCarcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube NeoplasmsImmunogen Inc2022-11-14
Adenocarcinoma, Clear Cell; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cystadenoma, Serous; Endometrial Neoplasms; Fallopian Tube Diseases; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Neoplasms
Details
Folinic AcidFTHFApproved
Anemia; Autism Spectrum Disorder; Colorectal Neoplasms; Diarrhea; Down Syndrome; Rectal Neoplasms; Vitamin B 12 Deficiency
Details
Customer Reviews
  • p***g2025-01-23
    As expected, this was a high quality product. I have purchased multiple products from Acro to develop assays in the past. As usual, purity and quantity was confirmed by our in-house quality control group. We are using this in conjunction with #FO1-H82E2 Biotinylated Human FOLR1 Protein, His Avitag. The product was used successfully in an immunization campaign and will also be used for other in-house assays in the future.
  • D***m2022-10-26
    We had to order human folate receptor protein for 100 micrograms unit type for one of our sensitive studies. It was crucial that the product work as intended. We received the product in a timely manner, and the product work as intended for one of our studies. As an employee working at a lab, I thank you for all the scientists working hard to make great products!
  • D***n2022-10-26
    We had previously ordered this product and we made the mistake of ordering the smaller quantity needed. We contacted customer support letting them know that we needed to switch the order to the larger quantity. They were friendly and helpful when resolving this issue. After the switch, the item in question was sent out very quickly and we were able to continue with our study as soon as it arrived.
  • S***h2022-09-09
    Received the protein really fast for SPR purposes. Experiments worked out really well with it. We were a little afraid that the His-NTA chemistry will not be a good fit for our work but the protein was truly modified and it really did bind to our sensors really well.
  • 1***62022-08-09
    Validated by SPR, measured monovalent affinity, anti-human FC chip, loaded diluted antibody, added diluted Folate R, His tag,with the affinity constant of 0.3 nM.
  • R***a2022-08-24
    I ordered human folate receptor alpha from Acro to test it in a variety of assays, including ELISA based interactions and functional folate binding studies. I have tested other folate receptors in the past and none have worked as well as the protein we have internally. Anyone can make a string of amino acids to be used as an antigen, but a functional protein (properly folded) is required for functional studies. Much to my surprise, the Acro protein was functional and bound labeled and unlabeled folic acid in a competitive binding assay, attached. I look forward to testing their other proteins in the future.